<DOC>
	<DOCNO>NCT02169141</DOCNO>
	<brief_summary>This open label observational pharmacokinetic drug study evaluate Levofloxacine Capreomycin patient Multidrug-Resistant Tuberculosis ( MDR-TB ) .</brief_summary>
	<brief_title>Pharmacokinetics Levofloxacin Capreomycin Multidrug-Resistant Tuberculosis Patients</brief_title>
	<detailed_description>Patients receive MDR-TB treatment o.a . Levofloxacin Capreomycin . At least one week start treatment , PK sample sample obtain via intravenous catheter 0 , 1 , 2 , 3 , 4 , 7 , 12 hour intake .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Multidrug-Resistant</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Capreomycin</mesh_term>
	<criteria>age &gt; 18yrs culture positive diagnosis MDRTB DM2 Pregnancy allergy IV canula material insertion IV canula possibele</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>MDR-TB</keyword>
	<keyword>Levofloxacin</keyword>
	<keyword>Capreomycin</keyword>
</DOC>